Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) EPS (Weighted Average and Diluted): 2022-2024

Historic EPS (Weighted Average and Diluted) for Insight Molecular Diagnostics (IMDX) over the last 3 years, with Dec 2024 value amounting to -$4.67.

  • Insight Molecular Diagnostics' EPS (Weighted Average and Diluted) rose 65.31% to -$0.34 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.47, marking a year-over-year increase of 24.25%. This contributed to the annual value of -$4.67 for FY2024, which is 1121.12% down from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported EPS (Weighted Average and Diluted) of -$4.67 as of FY2024, which was down 1,121.12% from -$0.38 recorded in FY2023.
  • Insight Molecular Diagnostics' EPS (Weighted Average and Diluted)'s 5-year high stood at -$0.38 during FY2023, with a 5-year trough of -$13.25 in FY2022.
  • For the 3-year period, Insight Molecular Diagnostics' EPS (Weighted Average and Diluted) averaged around -$6.10, with its median value being -$4.67 (2024).
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first spiked by 97.11% in 2023, then slumped by 1,121.12% in 2024.
  • Insight Molecular Diagnostics' EPS (Weighted Average and Diluted) (Yearly) stood at -$13.25 in 2022, then skyrocketed by 97.11% to -$0.38 in 2023, then tumbled by 1,121.12% to -$4.67 in 2024.